Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients With Unresectable and Locally-Advanced HCC

NCT05327738 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT05327738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05327738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients With Unresectable and Locally-Advanced HCC
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
December 10, 2022
Completion date
December 4, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, locally advanced hepatocellular carcinoma, recurrent hepatocellular carcinoma, unresectable hepatocellular carcinoma